Virax Biolabs Group's total inventories for the quarter that ended in Sep. 2025 was $0.05 Mil. Virax Biolabs Group's average total inventories from the quarter that ended in Mar. 2025 to the quarter that ended in Sep. 2025 was $0.07 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Virax Biolabs Group's Net-Net Working Capital per share for the quarter that ended in Sep. 2025 was $11.33.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Virax Biolabs Group's Days Inventory for the
six
months ended in Sep. 2025 was 13,596.25.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Virax Biolabs Group's Inventory Turnover for the quarter that ended in Sep. 2025 was 0.01.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Virax Biolabs Group's Inventory-to-Revenue for the quarter that ended in Sep. 2025 was 37.25.
Virax Biolabs Group (NAS:VRAX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Virax Biolabs Group's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Virax Biolabs Group's Inventory to Revenue for the quarter that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Virax Biolabs Group Total Inventories Related Terms
Virax Biolabs Group Total Inventories Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Virax Biolabs Group (VRAX) has a Total Inventories of $0.05 Mil as of Sep. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Total Inventories too high?
Virax Biolabs Group's current Total Inventories is $0.05 Mil. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Total Inventories compare to BBLG and PKTX?
Virax Biolabs Group's Total Inventories of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Virax Biolabs Group and its competitors. Virax Biolabs Group's current Total Inventories is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Total Inventories is $0.05 Mil. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Total Inventories is $0.05 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
Total Inventories: $0.05 Mil
GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score
Get the complete analysis for VRAX
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
